Two years ago, Hayley Grice, a 50-year-old financial director from Shropshire, wore a UK dress size 26 to 28. Today she wears a size 12. The difference, she says, is Mounjaro — the GLP-1 weight-loss injection made by Eli Lilly — and its consequences extend well beyond her wardrobe. "I would have shied away from colour, I would have shied away from anything that drew attention to me," she explains.
"And now I don't care, if I like it I'll wear it." That shift in consumer psychology, multiplied across millions of users, is beginning to register in the data that retailers and analysts watch most closely. New research from PwC estimates that roughly 5% of British adults — nearly 3 million people — are currently using GLP-1 drugs such as Novo Nordisk's Wegovy or Eli Lilly's Mounjaro, while 9% have taken one at some point. The consultancy projects that figure will reach 13%, or approximately 7 million people, by the end of next year.
Usage is heavily skewed by both gender and income: around 60% of current users are women, and 20% come from the wealthiest households, compared with just 6% from lower-income ones. The drugs are most prevalent among 25- to 44-year-olds, where uptake peaks at 13%, according to Mintel's Tamara Sender Ceron. The spending consequences are already measurable. Research from Circana and Mintel consistently shows that GLP-1 users eat less, switch to healthier foods, reduce alcohol consumption, and — critically for retailers — purchase more clothing, skincare, sportswear, and health-monitoring technology than they did before.
In the United States, where one in five adults has already tried a GLP-1 drug, shifts in grocery, alcohol, and apparel spending are described as noticeable.